Government wrong to push for Avastin in eye disease, says charity
May 12, 2011Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD
The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …
Roche aims for wholly personalised skin cancer drug
May 12, 2011Sales and Marketing Roche, personalised medicine, skin cancer, vemurafenib
Roche has submitted its key skin cancer drug vemurafenib to European and American regulators for approval. Vemurafenib (formerly RG7204) has …
AZ signs targeted colon cancer drug collaboration
May 11, 2011Research and Development AstraZeneca, colorectal cancer, personalised medicine
AstraZeneca has entered a partnership which intends to speed up the development of targeted treatments for colorectal cancer, a disease …
Drug regulators protect profits over patients, new study finds
May 11, 2011Research and Development Bad Science, Vioxx, regulatory affairs
Medicine regulators are protecting drug company profits over the welfare of patients by withholding trial data. That’s the verdict of …
New product can overtake Lantus, says Novo leader
May 11, 2011Sales and Marketing Novo Nordisk, degludec, diabetes, insulin
Novo Nordisk’s new insulin product can eclipse Sanofi’s Lantus within just a few years of its launch, according to Novo’s …
Verdict on AMT’s gene therapy expected soon
May 11, 2011Research and Development, Sales and Marketing AMT, Amsterdam Molecular Therapeutics, gene therapy, genes
Amsterdam Molecular Therapeutics says it will shortly receive the regulatory verdict on its gene therapy Glybera. Glybera (alipogene tiparvovec) is …
Digital Pharma: NICE puts guidance into online pathways
May 11, 2011Sales and Marketing Digital Pharma blog, NICE
NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways. NICE Pathways …
Service Insight: Clinical trials – managing route to market
May 11, 2011Research and Development Service Insight, Talking Point, research and development
SERVICE INSIGHT Clinical trials are notoriously difficult to manage and often fraught with problems, as they can involve many clinical …
Pfizer drops early-stage asthma candidate
May 11, 2011Research and Development Pfizer, Rigel, asthma
Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals. San Francisco-based Rigel says Pfizer is …
Wave Healthcare appoints former BMS medical liaison manager
May 11, 2011Medical Communications appointment, medical communications
Buckinghamshire-based med comms agency Wave Healthcare has appointed five new members of staff, including a former senior medical liaison manager …
Elan sells formulations unit to Alkermes for $960m
May 10, 2011Manufacturing and Production Alkermes, Elan
Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …
FDA fast-tracks Bayer’s GIST drug regorafenib
May 10, 2011Sales and Marketing Bayer, GIST, regorafenib
The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …
Digital Pharma: European doctors’ communities form major alliance
May 10, 2011Medical Communications Coliquio, Digital Pharma blog, Doctors.net.uk, Egora, Medcenter, doctors' social networks, meduniverse, online doctors communities
Europe’s largest online doctors communities have formed an alliance that could help pharma break through the language barrier to engage …
Merck KGaA sells South African manufacturing unit
May 10, 2011Manufacturing and Production Merck KGaA, Merck Pharmaceutical Manufacturing, Merck South Africa
Merck South Africa, a subsidiary of Germany’s Merck KGaA, has sold its manufacturing to a local private equity firm as …
Frank Walters joins Frontera as chairman
May 10, 2011Medical Communications appointment, medical communications
Healthcare comms start-up Frontera London has appointed industry veteran Frank Walters as its non-executive chairman. Frank was previously creative director …
Generic and API firms get latest crop of FDA warning letters
May 10, 2011Manufacturing and Production Cephazone, FDA, FDA warning letter, Ningbo Smart, Teva
Generic drugmakers Teva and Cephazone and API producer Ningbo Smart are the latest companies to receive warning letters from the …
French pharma firm denies drug risk cover up
May 10, 2011Sales and Marketing Mediator, Servier, drug safety
France’s second biggest pharma firm Servier has denied allegations it concealed risks associated with its diabetes drug Mediator (benfluorex). Research …
Sanofi name change sees Aventis dropped
May 9, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis
Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …
Alliance warns of ‘dumbing down’ of NHS reforms
May 9, 2011NHS reforms
The leader of the NHS Alliance has warned the current ‘pause’ in the NHS reforms could result changes which ‘dumb …
Pfizer’s Revatio extends Europe PAH licence
May 9, 2011Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio
Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
